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Carbapenem-resistant Acinetobacter baumannii (CR-AB) causes serious nosocomial
infections, especially in ICU wards of hospitals, worldwide. Expression of blaOXA
genes is the chief mechanism of conferring carbapenem resistance among CR-AB.
Although some blaOXA genes have been studied among CR-AB isolates from Iran,
their blaOXA-23-like genes have not been investigated. We used a multiplex-PCR to
detect Ambler class A, B, and D carbapenemases of 85 isolates, and determined
that 34 harbored blaOXA-23-like genes. Amplified fragment length polymorphism (AFLP)
genotyping, followed by DNA sequencing of blaOXA-23-like amplicons of CR-AB from
each AFLP group was used to characterize their blaOXA-23-like genes. We also assessed
the antimicrobial susceptibility pattern of CR-AB isolates, and tested whether they
harbored insertion sequences ISAba1 and ISAba4. Sequence comparison with reference
strain A. baumannii (NCTC12156) revealed five types of mutations in blaOXA-23-like
genes; including one novel variant and four mutants that were already reported from
China and the USA. All of the blaOXA-23-like genes mutations were associated with
increased minimum inhibitory concentrations (MICs) against imipenem. ISAba1 and
ISAba4 sequences were detected upstream of blaOXA-23 genes in 19 and 7% of isolates,
respectively. The isolation of CR-AB with new blaOXA-23 mutations including some that
have been reported from the USA and China highlights CR-AB pervasive distribution,
which underscores the importance of concerted national and global efforts to control the
spread of CR-AB isolates worldwide.
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INTRODUCTION
Carbapenem-resistant Acinetobacter baumannii (CR-AB) can
cause severe nosocomial infections particularly among patients in
intensive care units (ICUs) around the world (Safari et al., 2013).
Inadequate antimicrobial management of CR-AB infections
often gives rise to highly resistant strains leading to prolonged
hospitalization, treatment failures, and increased mortality
(Higgins et al., 2010a). Epidemics of multi-, extensively-, and
pandrug-resistant (MDR, XDR, and PDR) CR-AB have been
reported from several countries (Kempf and Rolain, 2011;
Bahador et al., 2013a; Moradi et al., 2015). In developing
countries, such as Iran, challenges in the treatment of CR-
AB infections are often exacerbated by widespread nosocomial
outbreaks of OXA-type β-lactamase producing MDR-AB (for
review see, Moradi et al., 2015). CR-AB are usually resistant
to several β-lactams through the expression of chromosomal
and plasmid-encoded carbapenemases including Ambler class A
(blaGES, and blaKPC), class B (blaIMP, blaNDM−1, blaSPM-1, and
blaVIM), and class D (blaOXA-23,40, and 58-like; Siroy et al., 2005;
Lu et al., 2009; Abbott et al., 2013). While the production of
OXA-23 by A. baumannii is sufficient to confer resistance to
carbapenems, insertion sequence (IS) elements ISAba1 and/or
ISAba4 upstream of blaOXA-23-like genes enhance the blaOXA–
mediated carbapenem resistance of CR-AB (Turton et al., 2006;
Lee et al., 2012; Evans and Amyes, 2014). Although there
are a few reports from Iran regarding the distribution and/or
frequency of the blaOXA-51-like genes among CR-AB, data about
characterization of their blaOXA-23 genes and ISAba elements is
not available.
In this study, we have characterized blaOXA genes in CR-
AB isolates from Iran, and report new variants that harbor
novel mutations in their blaOXA-23-like carbapenemase genes.
In addition to analyzing the distribution and frequency of
blaOXA-23-like genes, we have determined the antimicrobial
susceptibility patterns of isolates and the presence of ISAba1
and ISAba4 enhancer elements upstream of their blaOXA-23-like
genes. Characterization of blaOXA genes and assessment
of carbapenemase-mediated antibiotic resistance among A.
baumannii isolates can help efforts to develop databases, which
are essential to a comprehensive national surveillance program
in Iran, toward the local and global control of CR-AB outbreaks.
MATERIALS AND METHODS
Specimens and Bacterial Isolates and
Cultures
A total of 85 non-repetitive clinical specimens were collected
during 2011 from the intensive care units (ICUs) of Imam
Khomeini Medical Center (IKMC) and Children’s Medical
Center (CMC) in Tehran, Iran. IKMC and CMC are affiliated
with Tehran University of Medical Sciences (TUMS), and both
are large referral centers that provide tertiary health care to
patients from all over Iran. Specimens were collected from ICUs
in surgical (S), internal medicine (M), emergency (E), pediatrics
(P), and kidney transplantation (T) wards. Clinical isolates
were initially identified as A. baumannii using the API20NE
system (bioMérieux, Marcy-l’Etoile, France), and were further
confirmed by gyrB multiplex PCR, as described previously
(Higgins et al., 2010b). Specimen sources for A. baumannii
isolates were as follows: respiratory tract (n = 51), urine (n =
16), blood (n = 11), wound (n = 5), and cerebral spinal fluid
(CSF; n = 2). Twenty six of the A. baumannii isolates were
part of a previous molecular epidemiologic study (Bahador et al.,
2014). Brain heart infusion (BHI) agar plates andMueller-Hinton
broth (MHB; both from Merck, Germany) were used to culture
the bacterial isolates.
Antimicrobial Susceptibility Testing
To assess susceptibility of A. baumannii clinical isolates,
the disk agar diffusion (DAD) method (CLSI, 2015) was
carried out according to the Clinical and Laboratory Standards
Institute (CLSI) procedures and breakpoint interpretations, using
antimicrobial disks containing 19 different antimicrobial agents
(Mast Diagnostics, Bootle, UK; Table 2). The CLSI guideline for
broth microdilution test for minimum inhibitory concentrations
(MICs) was used to assess the susceptibility of MDR-AB isolates
to colistin (CST), imipenem (IPM), rifampicin (RIF), and
tigecycline (TGC). For tigecycline susceptibility tests, the criteria
of the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for Enterobacteriaceaewere used, in which an
MIC of<1µg/mL was defined as susceptible and>2µg /mL was
considered resistant (EUCAST, 2015). Rifampicin susceptibility
was interpreted according to CLSI criteria using breakpoint
values suggested for Staphylococcus aureus, in which susceptible
and resistant were defined as ≤1µg/mL and ≥4µg/mL,
respectively (CLSI, 2015). A. baumannii isolates were defined as
MDR, XDR, and PDR according to the definitions provided by
Magiorakos (Magiorakos et al., 2012). The MIC geometric mean
(MICgm) of imipenem against blaOXA-23-like
+ CR-AB isolates
were also compared with the MICgm of non-mutant isolates,
and fold-increase calculations were measured against MICgm of
non-mutant strains.
Detection of Carbapenemase Gene ISAba1
and ISAba4 Insertion Sequences
The overall strategy for the identification of the 34 blaOXA-23-like
+
CR-AB isolates is shown in Supplemental Figure 1. Briefly,
we tested all 85 A. baumannii isolates for carbapenemase
production by the modified Hodge test (Lee et al., 2012),
and their chromosomal DNA were tested by two different
confirmatory multiplex-PCR assays to identify the most
common carbapenemase encoding genes. The criteria to
include isolates in this study were the presence of PCR-specific
amplicons, confirmed by agarose gel electrophoresis analysis
(Supplemental Figure 1). A novel in-house multiplex-PCR,
referred to as AB-hexaplex-PCR was optimized for the rapid and
simultaneous detection of the most common carbapenemase
genes, including Ambler class A and B (blaKPC, blaGES, blaIMP-1,
blaVIM-2, blaNDM-1, and blaSPM-1) in A. baumannii using Primer
3 software (version 4.0; http://primer3.wi.mit.edu/; accessed
June 05, 2011). Reference gene sequences were accessed from
GenBank [http://www.ncbi.nlm.nih.gov/GenBank (blaKPC:
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GQ140348, blaGES: GU207844, blaIMP-1: EF375699, blaVIM-2:
GQ288396, blaNDM-1: JN794561, and blaSPM-1: HM370523;
accessed June 04, 2011)], as shown inTable 1. The Ambler class D
type carbapenemase genes (blaOXA-23,24,51,58 like) were detected
using the Woodford multiplex PCR assay method (Woodford
et al., 2006). Additionally, the AB-hexaplex-PCR distinguished
amplicons corresponding to the blaIMP-1, blaSPM-1, blaGES and
blaKPC, blaNDM-1, and blaVIM-2 genes, and isolates that harbored
these genes were excluded from our study (representative gel;
Supplemental Figure 2). The frequency of ISAba1 and ISAba4
elements upstream of blaOXA-23-like and blaOXA-51-like genes
were assessed using a series of PCR amplifications. A set of
primers, referred to as ISAba1F/OXA-23R, ISAba4F/OXA-23R,
and ISAba1F/OXA-51R, is shown in Table 1. After our serial
TABLE 1 | Primer sequences and adaptors (and their corresponding reference) utilized in order to identify most common carbapenemase genes in our
isolates, and to generate amplicons for AFLP genotyping analysis.
Assay Primer Sequence (5′-3′)† Size of amplicon References
Detection of carbapenemase in
the molecular class D
Multiplex PCR blaOXA-51 likeF TAATGCTTTGATCGGCCTTG 353 Woodford et al., 2006
blaOXA-51 likeR TGGATTGCACTTCATCTTGG
blaOXA-23 likeF GATCGGATTGGAGAACCAGA 501 "
blaOXA-23 likeR ATTTCTGACCGCATTTCCAT
blaOXA-24 likeF GGTTAGTTGGCCCCCTTAAA 240 "
blaOXA-24 likeR AGTTGAGCGAAAAGGGGATT
blaOXA-58 likeF AAGTATTGGGGCTTGTGCTG 590 "
blaOXA-58 likeR CCCCTCTGCGCTCTACATAC
Detection of carbapenemase in
the molecular classes A and B
hexaplex PCR (h-PCR) IMP-1F AACATGGTTTGGTGGTTCTTGT 263 Present study
IMP-1R TCCGCTAAATGAATTTGTGGCT
VIM-2F CAATGGTCTCATTGTCCGTGAT 395 "
VIM-2R AAATCGCACAACCACCATAGAG
NDM-1F CTGGATCAAGCAGGAGATCAAC 118 "
NDM-1R ATTGGCATAAGTCGCAATCCC
KPCF CGCTAAACTCGAACAGGACTTT 640 "
KPCR ATAGTCATTTGCCGTGCCATAC
blaGESF GAAAACTTTCATATGGGCCGGA 567 "
blaGESR GACCGACAGAGGCAACTAATTC
SPM-1F CCATTGTCTGCAAAAAGTTCGG 439 "
SPM-1R AAACATTATCCGCTGGAACAGG
ISAba1 detection upstream of
blaOXA-51
IsAba-1 F/OXA-51 R IsAba-1 F AAGCATGATGAGCGCAAAG 227 "
OXA-51 R GGTGAGCAGGCTGAAATAAAA
ISAba1 detection upstream of
blaOXA-23
IsAba-1 F/OXA-23 R IsAba-1 F TGAGATGTGTCATAGTATTC 314 "
OXA-23 R AGAGCATTACCATATAGATT
ISAba4 detection upstream of
blaOXA-23
IsAba-4 F/OXA-23 R IsAba-4 F CACAATTTCTGATAAAGATA 327 "
OXA-23 R TTTATTAAATTATGCTGAAC
AFLP Adaptors adp MbI GTAGCGCGACGGCCAGTCGCG No amplicon Bahador et al., 2013b
ADP MbI GATCCGCGACTGGCCGTCGCGCTAC
adp MsI GTAGCGCGACGGCCAGTCGCGT "
ADP MsI TAACGCGACTGGCCGTCGCGCTAC
Pre-amplification PreAmp Mbo ACGGCCAGTCGCGGATC Multiple and variable "
PreAmp Mse CGACGGCCAGTCGCGTTAA
Selective primers Mbo1 PreAmp Mbo + A Multiple and variable "
Mbo2 PreAmp Mbo + T
Mbo3 PreAmp Mbo + C
Mbo4 PreAmp Mbo + G
Mse1 PreAmp Mse + A
Mse2 PreAmp Mse + T
Mse3 PreAmp Mse + C
Mse4 PreAmp Mse + G
†
Nucleotide.
Frontiers in Microbiology | www.frontiersin.org 3 November 2015 | Volume 6 | Article 1249
Bahador et al. ISAba elements and blaOXA-23-like genes
screening of isolates, 34 isolates were identified that harbored
blaOXA-23-like gene as their sole acquired carbapenemase gene.
AFLP Genomic Fingerprint Analysis
Amplified fragment length polymorphism (AFLP) genotyping
of blaOXA-23-like
+ and blaOXA−51−like
+ isolates was carried out
by a modified Vos method (Vos et al., 1995), as described
previously (Bahador et al., 2013b). AFLP typing was carried
out prior to sequence analysis to ensure thorough examination
of the diversity of CR-AB isolates. Briefly, chromosomal DNA
was size-verified and double-digested with MboI and MseI
(Fermentas, Lithuania). Then DNA fragments were ligated to
corresponding adapters using T4 DNA ligase (350 U/µ L,
Takara Bio, Japan) followed by the preliminary PCR using
PreAmp-Mbo and PreAmp-Mse primers (Table 1). Preliminary
PCR amplicons served as templates for selective PCR, which
generated AFLP genotype profiles upon agarose gel analysis.
Initial testing of 36 combinations of primers, including PreAmp
Mbo (PreAmp Mbo+A, +T, +C, +G), and PreAmp Mse
(PreAmpMse+A,+T,+C,+G) and A. baumanniiNCTC12156
DNA as a normalization reference showed that the Mbo4-
Mse4 combination generated the clearest AFLP profiles when
analyzed using BioNumerics version 5.10 (Applied Maths, Sint-
Martens-Latem, Belgium). The similarity between band patterns
was calculated using the Dice coefficient, with an optimization
of 0.5% and a position tolerance of 1%. The AFLP types
were grouped at the 90% similarity cutoff on a dendrogram
constructed by the unweighted-pair group method using average
linkages (UPGMA).
DNA Sequencing of blaOXA-23-like Genes
To evaluate an association between changes in the chromosomal
carbapenemase gene sequence of isolates and their antimicrobial
resistance pattern, a two-step approach was adopted. An initial
AFLP assay was carried out on blaOXA-23-like
+ CR-AB, followed
by DNA sequence analysis of the blaOXA-23-like gene of a
representative isolate from each AFLP genotype group.
Briefly, we used a high fidelity Pfu DNA polymerase
(Fermentas, Lithuania) to generate blaOXA-23-like specific
amplicons, which were purified using a AccuPrep R© PCR
Purification Kit (Bioneer, Daejeon, Korea) and cloned into
pTZ57R (InsT/A Clone PCR product cloning kit, Fermentas,
Vilnius, Lithuania). DNA was then transferred into competent E.
coli TOP10 cells, which were then isolated using Luria-Bertani
(LB) agar supplemented with ampicillin (100µg /mL). Plasmid
DNA was prepared with the AccuPrep Plasmid MiniPrep DNA
Extraction Kit, (Bioneer, Daejeon, Korea) and sequenced using
an ABI3730 automatic sequencer (Applied Biosystems, CA,
USA). The sequences were analyzed using a BLAST algorithm
against the NCBI GenBank database [http://www.ncbi.nlm.nih.
gov/guide/dna-rna/ (accessed 05.06.11)].
Iodometric Assay of β-lactamase Activity
Bacterial β-lactamase enzymatic activity was determined by an
iodometric assay, as described previously (Sawai et al., 1978).
Briefly, crude lysates of 16 isolates that represented AFLP groups
were extracted using the Saino method (Saino et al., 1982).
Briefly, overnight bacterial growth were diluted in MHB broth
to a concentration of 107 cfu/ml and incubated in a shaker
for 2 h at 35◦C. As an inducer, imipenem was added at 0.25
of the isolate MIC and incubated for an additional 2 h (Clark,
1996). Bacterial cells were harvested, centrifuged at 4◦C, washed
twice with 50mM phosphate buffer saline (PBS; pH 7.0), and re-
suspended in 0.1M PBS (pH 7.0). The suspension was sonicated
in an ultrasonic disrupter (Branson Ultrasonics Co., Shanghai,
China) at 75 W for 3min in an ice bath; afterward the disrupted
cell suspension was centrifuged at 13,000 × g for 30min at
4◦C. The β-lactamase enzymatic activity of the supernatant fluid
(i.e., bacterial lysate) was measured against imipenem using
iodometric method described by Doust (Daoust et al., 1973)
using reagents prepared, as described previously (Onishi et al.,
1974; Sawai et al., 1978; Minami et al., 1980). Briefly, iodine
reagent (40µmol in 0.5M acetate buffer, pH 4.0) was added to
lysate supernatant fluids, after 5min incubation with imipenem
(50µg/mL) at 30◦C. Ten minutes later, samples’ absorbance was
measured at 620 nm, and imipenem hydrolysis was determined.
Activity was reported as the mean of triplicate samples in
micromoles of imipenem degraded per minute per milligram
of protein in each bacterial extract. Protein concentrations were
measured by Bradford assay kit (Pierce™ Coomassie Plus Assay
Kit, Thermo Scientific, Ottawa, Canada).
In Silico Analysis and Nucleotide Sequence
Accession Numbers
In silico analysis was carried out using GenBank nucleotide
database. Predict Protein software (hosted by Rostlab) was
also used to predict changes as a result of a frameshift
mutation. The nucleotide sequence data were deposited in
the GenBank nucleotide database under accession numbers:
JQ343842.1, JQ343840.1, JQ343838.1, JQ343836.1, JQ343841.1,
JQ343839.1, JQ343837.1, JQ360584.1, JQ360582.1, JQ360580.1,
JQ360578.1, JQ360583.1, JQ360581.1, JQ360579.1, JQ360577.1,
and JQ061320.1. The novel DNA sequence of blaOXA 23 genes,
with “No Full-Match” by GenBank; as well as its corresponding
peptide amino acid sequence was submitted to Lahey database
(lahey.org/Studies).
RESULTS
Antimicrobial Susceptibility Profiles and
AFLP Genomic Fingerprint Analysis
Table 2 shows the susceptibility profiles of all 85 CR-AB isolates
against CLSI groups of antimicrobial agents. Overall, CR-AB
isolates were most resistant to CLSI group A (51–96%), followed
by group B (25–97%) antimicrobials. Overall, up to 96% of
isolates were resistant to 12 of the tested antimicrobials; while
the rates of resistance to tigecycline, imipenem, and doripenem
were 34, 65, and 94%, respectively. The lowest resistance
rates among isolates were against colistin (12%), minocycline
(25%), and doxycycline (31%). Interestingly, all colistin-resistant
isolates were susceptible to tigecycline and/or tobramycin. The
frequency of MDR, XDR and PDR isolates were 69, 24, and
0%, respectively; and broadly-resistant CR-AB isolates were most
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frequently recovered from the surgical and internal medicine
ICU wards. However, the frequency of resistant isolates was
generally proportional to the number of specimens from each
ICU (Table 2).
Our analysis revealed that 34 (40%) isolates harbored
blaOXA-23-like genes, and 51 isolates were resistant to
carbapenems but did not harbor blaOXA-23-like genes
(Supplemental Figure 1). AFLP genotype analysis of
blaOXA-23-like
+ isolates generated 16 distinct AFLP genotypic
groups, labeled genotype A through P. Group C (n = 6) was
the predominant AFLP type, followed by genotype I (n = 4),
and genotypes B, K, L, and N (n = 3 in each group). While
each AFLP group consisted of 1 to 6 isolates, 50% (8/16) of the
groups consisted of a single isolate, indicative of a high diversity
among CR-AB isolates. Despite this diversity, the antimicrobial
susceptibility patterns among 13 (82%) genotypes were similar,
with the exception of genotypes A, M, and N (Figure 1).
Detection of ISAba1 and ISAba4
Overall, ISAba1 and ISAba4 sequences were present in 61%
and 7% of all tested CR-AB isolates, respectively. Among 34
blaOXA-23-like
+ isolates, 67% were ISAba1+, and 18% were
ISAba4+ (Figure 1); whereas 10 (63%) and 3 (19%) of AFLP
genotypes harbored ISAba1 and ISAba4 elements, respectively.
ISAba4 was only present among AFLP types G, E, and K
isolates, while genotypes A, M, and N has neither ISAba1, nor
ISAba4 element (Table 3; Figure 1). Interestingly, even though
the ISAba1+ isolates of genotype B (N = 3) exhibited an
XDR profile, all genotype B isolates remained susceptible to
tobramycin and ampicillin–sulbactam.
Among the blaOXA-23-like
+ isolates that harbored either
ISAba1 or ISAba4 elements, a majority (82%) displayed a
distinctive profile of resistance to 9 antimicrobial agents, namely,
CAZ, CRO, CTX, DOR, FEP, IPM, PIP, SAM, and TZP
(Figure 1). The presence of either ISAba1, or ISAba4 imparted
resistance to imipenem and doripenem among blaOXA-23-like
+
genotypes. However, the genotype A isolate (which was ISAba1−
and ISAba4−) also showed resistance to imipenem (MIC =
16µg/mL).
Sequence Analysis of blaOXA-23-like Genes
Table 3 demonstrates sequence differences between the
blaOXA-23-like specific amplicon among members of AFLP
groups vs. the blaOXA-23 sequence of the A. baumannii reference
strain (referred to as “wild type”). The blaOXA-23 gene sequences
of six (37%) AFLP genotypes did not differ from the wild-
type strain; however, isolates from 10 (63%) AFLP types had
mutations in blaOXA-23 genes. Five different blaOXA-23 gene
mutations were detected, and a Genbank search revealed that
one of the mutant sequences had been recently reported from the
USA, namely blaOXA-366, and three were reported from China
(i.e., blaOXA-422, 481, and 482-like genes). One novel blaOXA-23-like
gene sequence was thus submitted to the Lahey database and
assigned as the blaOXA-495-like gene.
At the points of carbapenemase gene mutations, comparison
of a 21-nucleotide sequence of PCR amplicons obtained from
isolates in mutant AFLP groups that had >2 members, i.e.,
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FIGURE 1 | Dendrogram of amplified fragment length polymorphism (AFLP) analysis of genomic DNA extracted from bla
(+)
OXA-23-like CR-AB isolates.
Susceptibility to select antimicrobials and ISAba presence is also indicated. Dice coefficient with 0.5% optimization and 1% position tolerance was used. Dendrogram
was constructed by unweighted-pair group method using average linkages (UPGMA); and AFLP type identification was defined by groups formed at 90% similarity
cutoff. aFEP, cefepime; IPM, imipenem; SAM, ampicillin-sulbactam; TZP, Piperacillin/tazobactam. bAll 16 AFLP types were resistant to the following beta-lactam
antimicrobial agents: CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; PIP, piperacillin; TIM, ticarcillin/clavulanic acid.
groups L, E, C, and K, showed strong homologies within these
AFLP types (Supplemental Figure 3). Additionally, Table 3
displays the AFLP type, imipenem MIC, and ISAba status
among various blaOXA-23
+ isolates according to their specimen
source. The absence of mutation(s) in blaOXA-23 genes was
associated with lower imipenem MICs as compared to mutant
isolates. Imipenem MICgm for all non-mutant blaOXA-23 gene
isolates was 16µg/mL (range = 8 − 32µg/mL), whereas the
mean MIC for mutants was almost 50µg/mL (range = 16 −
128µg/mL). Conversely, alterations of the blaOXA-23 gene were
associated with an increased MIC to imipenem among A.
baumannii isolates. While 16 (47%) of blaOXA-23-like
+ isolates
harbored ISAba1 sequences upstream of their carbapenemase
gene, only six (18%) isolates were ISAba4+. ISAba1 elements
were detected upstream of either blaOXA-23 or blaOXA-51 genes,
orboth these genes.Since, none of the blaOXA-23-like
+ isolates
were both ISAba1+ and ISAba4+, the presence of these elements
appeared mutually exclusive among isolates (Table 3). The
ISAba4 sequence was absent among blaOXA-23-like genes of non-
mutant CR-AB isolates, whereas six of mutant isolates, namely
genotypes G, E, and K, were ISAba4+ with moderate MICs,
ranging from 16 to 64µg/mL (Table 3). Althoughmutant isolates
of genotypes C and D were ISAba1+ had the highest imipenem
MICs (128µg/mL), the imipenem MIC of ISAba1+ mutants
among genotypes O, P, J, and L was 16µg/mL. Furthermore,
all ISAba1− and ISAba4− CR-AB isolates had non-mutant
blaOXA-23
+ genes, namely genotypes A, M, and N isolates,
which showed the lowest imipenem MICs (8–16µg/mL), as
well. Surprisingly, three blaOXA-23-like
+ isolates (genotypes A
and M) had imipenem MICs of 16µg/mL, but harbored neither
ISAba1, nor ISAba4 elements upstream of the blaOXA-23-like
gene, suggestive of other resistance mechanisms in these isolates
(Table 3).
As shown in Table 3, among mutations of the blaOXA-23-like
genes, insertions/deletions at nucleotide positions 335 and 336
were most frequent (40%), followed by a single substitution at
position 771 (30%). Isolates with F, G, O, and P genotypes showed
the insertion/deletion mutations at position 335, with imipenem
MICs of 16–32µg/mL, whereas isolates with genotypes E, C, and
K had the substitution at position 771 and showed the highest
imipenem MICs of 64–128µg/mL (Table 3). Further analysis
revealed that three other single substitutions also occurred
at positions 376, 625, and 766 among genotypes J and L,
but their imipenem MICs were not higher than non-mutants
(16µg/mL). In addition, three isolates with the substitution at
position 771 had a 3–4-fold increase in imipenem MIC over
that of the non-mutants. A frame-shift mutation at position
355, which corresponds to a change at aa112–118, in genotype
D isolate (strain TUMS/BTRF 661) was associated with a
four-fold increase in imipenem MICgm (128µg/mL) over that
of non-mutant isolates. Software prediction showed that the
frame-shift mutation may change the subcellular localization
of carbapenemase and enhance its secretion rate, which can
explain the high MIC of the isolate against carbapenems. In silico
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TABLE 3 | Comparison of blaOXA-23-like gene sequences among CR-AB isolates belonging to various AFLP genotype groups, as compared to blaOXA-23
gene sequence of A. baumannii reference strain, according to the specimen source, MIC against imipenem, β-lactamase activity, and ISAba element
status.
No. Isolates AFLP type
(No.)
Specimen
(ICU)a
Nucleotide Change(s) Amino Acid
Change(s)
MIC of IMP
(mg/L)
Mean of
β-lactamase
activityd (SD)e
ISb type
ISAba 1 ISAba 4
1 blaOXA-23 N (3) Urine (S) None None 8 ND − −
2 " M (2) Urine (S) " " 16 1.05(0.10) − −
3 " A (1) Urine (S) " " 16 0.87(0.04) − −
4 " H (1) Blood (P) " " 32 2.63(0.15) + −
5 " I (4) Blood (E) " " 16 1.35(0.09) + −
6 " B (3) CSF (S) " " 16 ND + −
7 blaOXA-482 F (1) Urine (M) Insertion of A at position 335 and
deletion of A at position 336
Ser Tyr
at aa 112
32 0.42(0.04) + −
8 " G (1) Urine (T) " " 16 5.58 (0.91) − +
9 " O (1) Urine (E) " " 16 2.11(0.63) + −
10 " P (1) Sputum (E) " " 16 2.35(0.87) + −
11 blaOXA-481 E (2) Wound (S) G A
at position 771
Met Ile
at aa 257
64 1.67(0.09) − +
12 " C (6) Urine (S) " " 128 7.96(0.92) + −
13 " K (3) Blood (M) " " 64 7.75(1.03) − +
14 blaOXA-495 D (1) Sputum (S) Frame-shift due to insertion of A
at position 335 and deletion at A
at position 354
Change in
aa112–aa118
motifc
128 14.37(1.33) + −
15 blaOXA-366 J (1) Blood (M) A C
at position 376, and
G A
at position 625
Met Ile
at aa 126, and
Glu Lys
at aa 209
16 2.62(0.53) + −
16 blaOXA-422 L (3) Sputum (S) G A
at position 766
Glu Lys
at aa 256
16 0.37(0.03) + −
a ICUs: E, Emergency; M, Medical Care; P, pediatric; S, surgical; T, transplantation.
b IS: Insertion sequence.
cSFTAWE YIYRLG.
d
µmole imipenem hydrolyzed per min permg of protein.
estandard deviation.
ND, No detactable activity.
comparison of carbapenemase binding domains of wild-type vs.
the frame-shift mutant also showed that the binding domain
changed from “aa15–24 and aa28–29” to “aa15–22 and aa24–
25” motif, which may lead to higher affinity of mutant OXA-23
enzyme for the binding cleft of carbapenems.
Five blaOXA-23 mutants and one non-mutant isolate showed
imipenem MICs of >16µg /mL. Further in silico analysis
revealed that the blaOXA-23-like gene mutations would lead
to up to six amino acid changes in the carbapenemase
protein. However, the highest imipenem MICs were associated
with a single substitution at position 771 of blaOXA-23-like
gene, corresponding to aa 257 substitution in carbapenemase
among genotypes E, C, and K, which represented 55% of the
mutant isolates. All AFLP types with non-mutant blaOXA-23
genes showed MICs of ≤16µg/mL for imipenem, except
the genotype H isolate (MIC = 32µg /mL); however, all
blaOXA-23-like mutants showed high imipenem resistance (MIC=
16–128µg/mL).
As shown in Table 3, we compared the β-lactamase activity
of the 16 representative isolates from each AFLP group.
Overall, the range of β-lactamase activity of non-mutant
isolates was lower (not detectable–2.63µmoles/min/mg protein)
than the blaOXA-23-like mutants (0.37–14.37µmoles/min/mg
protein). Mutant isolates, such as the frame-shift mutant
genotype D, showed the highest imipenem MICs (i.e., 64
and 128µg/mL), as well as the highest β-lactamase activities,
i.e., 7.96 and 14.37µmoles/min/mg protein for genotype C
and K, respectively. In contrast, lysates from isolates with no
blaOXA-23-like gene mutation that had the lowest MICs (e.g.,
genotypes N and B), and showed no detectable β-lactamase
activity. The β-lactamase activity of a imipenem-susceptible
(MIC < 4µg/ml), clinical A. baumannii isolate, was also below
assay’s detection level (data not shown). Among the 4 isolates
that had the same mutation at position 335, the β-lactamase
activity was between 0.42 and 5.58µmoles/min/mg protein,
while imipenem their MIC was 16–32µg/mL. However, with
the exception of genotype E, the β-lactamase activity of mutants
with position 771mutation, was increased concomitant with high
MICs in these isolates. The majority (70%) of mutant isolates
were recovered from two ICU wards; namely, the surgical (n =
4), and the internal medicine (n = 3) ICU; however, no mutant
isolates were recovered from the pediatric ICU ward. Among the
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blaOXA-23-like mutant isolates, eight (80%) were recovered from
either urine or sputum specimens (Table 3).
Table 4 shows the distribution of ISAba1 or ISAba4 sequences
upstream of various blaOXA-23- and blaOXA-51-like genes among
the isolates that harbored ≥1 carbapenemase genes; and also
their resistance rate against carbapenems. The presence of
ISAba upstream of the blaOXA-51-like andblaOXA-23-like genes was
associated with high rate of carbapenem resistance. Among all
blaOXA-51-like
+ or blaOXA-23-like
+ isolates, almost 32% (n = 27)
lacked either ISAba1, or ISAba4 sequences. CR-AB isolates were
consistently more resistant to doripenem than to imipenem,
regardless of their blaOXA- genes (Table 4). There was no marked
difference in carbapenem resistance rates whether the isolates
harbored the “blaOXA-51-like gene alone,” or “blaOXA-51-like
plus blaOXA-24-like” genes. Overall, the ISAba1 element was
more often associated with blaOXA-51-like gene (20–100%) than
with blaOXA-23-like genes; and ISAba
+ isolates showed high
rates of carbapenem resistance, especially against doripenem.
Despite this high resistance rate, 13% of blaOXA-23
+/blaOXA-51
+
isolates that harbored both ISAba1 and ISAba4 were imipenem
susceptible (Table 4). Among ISAba+ isolates, these elements
were upstream of the blaOXA-51-like gene in 60% (31/52) of
the isolates, whereas only 31% harbored ISAba1 upstream of
the blaOXA-23-like gene. All 13 (15%) CR-AB isolates with
blaOXA-51-like gene as their sole carbapenamase gene had ISAba1
elements. Interestingly, even though test isolates showed an
overall high resistance rate against carbapenems, 32% of isolates
did not harbor either ISAba1 or ISAba4 elements. By and large,
there was no marked change in resistance rate among isolates
that harbored the blaOXA-24-like gene in combination with other
carbapenemase genes (Table 4).
DISCUSSION
Infections caused by carbapenem-resistant A. baumannii are
among the most difficult to treat, especially among ICU
patients (Alfandari et al., 2014). In several countries, including
Iran, clinicians face serious challenges in choosing an effective
combination of antimicrobial agents while treating patients with
severe nosocomial CR-AB infections. Efforts to control MDR-AB
outbreaks have prompted widespread use of antimicrobials, such
as tigecycline and colistin, as therapeutic measures to combat
severe infections (Garnacho-Montero et al., 2015). However,
appropriate treatment and effective infection control measures
require local susceptibility patterns, as well as molecular
epidemiologic data, such as the blaOXA gene status of CR-AB
isolates. Several surveillance studies have reported widespread
nosocomial outbreaks of OXA-type producing A. baumannii,
and a high prevalence of blaOXA gene-carrying CR-AB in Iran,
but data regarding their blaOXA-23-like gene is not available
(Moradi et al., 2015).
In the present study, we have genetically evaluated
blaOXA-23-like
+ CR-AB isolates and found high genotypic
diversity among the isolates, including variants with new
blaOXA-23-like gene mutations. These mutations were associated
with up to four-fold increases in MIC levels against imipenem, as
compared to non-mutant isolates. Mutations in certain codons
associated with a high degree of resistance to imipenem. For
instance, substitutions at position 355 of the blaOXA-23-like gene
(i.e., the frame-shift mutation) were associated with high-level
resistance, whereas position 256 mutations were associated
with low-level resistance. Surprisingly, newly-found mutations
correspond to regions of the carbapenemase molecule that
TABLE 4 | Frequency of ISAba1 or ISAba4 sequences upstream of various blaOXA- genes among test CR-AB isolates that harbored ≥ 1 carbapenemase
genes, and the comparison of percent resistance against carbapenems among CR-AB isolates according to the isolate’s blaOXA- gene combination.
No. Carbapenemase gene(s)
of CR-AB isolates
(Total=85)
% of isolates with insertion sequences % Carbapenem
Resistancea
ISAba1 on
bla OXA-51-like(n = 31)
ISAba1 on
bla OXA-23-like(n = 16)
ISAba1 on
bla OXA-51-likeand
bla OXA-23-like (n = 5)
ISAba4 on
bla OXA-23-like
(n = 6)
Without
ISAba
(n = 27)
DORb IPM
1 blaOXA-51-like (n = 13; 15%) 38 – – – 62 77 46
2 blaOXA-51-like and
blaOXA-23-like (n = 54; 63%)
37 30 9 9 15 100 72
3 blaOXA-51-like and
blaOXA-24-like(n = 10; 12%)
30 – – – 70 90 40
4 blaOXA-51-like,
blaOXA-23-like and
blaOXA-24-like(n = 5; 6%)
20 0 0 20 60 100 80
5 blaOXA-51-like,
blaOXA-23-like,
blaOXA-24-like and
blaOXA-58-like (n = 1; 1%)
100 0 0 0 0 100 100
6 blaOXA-51-like and vim-2
(n = 2; 3%)
50 0 0 0 50 50 50
aMIC ≤ 8 ug/ml.
bDOR, doripenem; IPM, imipenem.
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are outside the standard “S-T-F-K, S-X-I, Y-G-N” and “K-S-
G” oxacillinase motifs (Couture et al., 1992), suggesting that
configurational changes due to novel mutations may also affect
oxacillinase activity against carbapenems.
Although a high frequency of MDR (69%) and XDR (24%)
A. baumannii isolates from this region is consistent with
previous reports (D’Arezzo et al., 2011; Potron et al., 2011;
Sung et al., 2011), our finding of 26 and 6% increases in
resistance to tigecycline and colistin, respectively, (Bahador
et al., 2014) is quite worrisome. Fortunately, while all isolates
harboring mutations in blaOXA-23-like genes showed resistance to
carbapenem-class antibiotics; they were susceptible to tigecycline
and/or tobramycin, which concurs with a recent report that
shows potential activity of a number of combinations against
MDR A. baumannii (Garnacho-Montero et al., 2015). Our data
regarding to a high prevalence of blaOXA-23-like genes among
CR-AB from Tehran confirms previous reports (Shahcheraghi
et al., 2011), and implies that extra efforts should be focused
on controlling the spread of blaOXA-23-like
+ A. baumannii in
this area. Clonal outbreaks of OXA-23-producing CR-AB have
been reported from several countries (Mugnier et al., 2010).
Interestingly, isolates in this study did not harbor any NDM-
1 metallo-β-lactamase genes, nor the “blaSPM−1 and blaGES−1”
genes, which have recently been reported from India and Pakistan
(Jones et al., 2014; Sartor et al., 2014), and Tehran (Shahcheraghi
et al., 2011), respectively. However, we detected three mutant
blaOXA-23-like genes with identical sequences reported from
China.
The data on the presence of ISAba1 sequences upstream from
blaOXA genes and enhancement of OXA–enzyme expression
confirms previous reports (Sung et al., 2011); however, these
findings are in contrast with a report from northwestern Iran,
which detected no ISAba1 sequences upstream of the blaOXA
gene (Peymani et al., 2012). Together, these results suggest that
the CR-AB populations in various parts of Iran are diverse and
distinct, which may hint on probable differences in antimicrobial
management of A. baumannii infections in various regions.
Moreover, most of the blaOXA-23 mutant A. baumannii isolates
were obtained from urine and sputum samples, suggesting
that specific infection control protocols regarding urinary
catheters and ventilators are possible primary sources of CR-AB
transmission.
Although increased imipenem resistance due to a mutation
in the blaOXA-23 gene has been reported previously (Lin et al.,
2011), to the best of our knowledge, this is the first report of CR-
AB blaOXA-23 gene mutants from Iran. It is noteworthy that the
TUMS/BTRF661 strain showed the highest MIC (128µg/mL),
implying a greater influence of the frame-shift mutation on
carbapenem resistance than any of the substitution mutations.
Our future studies will focus on exploring the difference in
the MICs of the various mutants (16 vs. 128µg/mL) and the
potential complex interactions between antimicrobial agents
and carbapenemase at the molecular level, where the position
of the affected motif plays a critical role. While production
of carbapenemase remains to be the chief mechanism of
carbapenem-resistance in A. baumannii, whether additional
factors, such as alterations in outer membrane permeability,
eﬄux pumps as with AdeABC (Potron et al., 2015), or OprD
porin (Potron et al., 2015), contribute to carbapenem-resistance
amongmutants. The variability in the β-lactamase activity and
MIC values of variants that share a mutation, suggests that other
factors play a role in high MIC levels among mutant CR-AB
isolates, and they remain to be explored.
Assuming future confirmation of the correlation of specific
mutations with high MICs, carbapenem resistance levels may
be predictable by DNA sequence-based detection methods. Also,
determination of predominant blaOXA-23 genotype(s) of isolates
in various areas and their blaOXA-23-like gene mutations may
serve as a tool for molecular epidemiologic investigations to
control the spread of CR-AB infections. While the present study
focused on the chromosomal OXA-encoding genes in CR-AB, we
also plan to explore the role of mutations in plasmid-encoded
blaOXA-23-like genes among carbapenem-resistant A. baumannii,
since many of these genes are plasmid-borne.
In conclusion, we report the identification of CR-AB variants
that harbor blaOXA-23-like gene mutations, which are associated
with an increased MIC against imipenem. Several blaOXA-23-like
mutant isolates are widespread and have been reported from the
USA, and China. The detection of new blaOXA-23 mutant isolates
from Iran highlights the importance of concerted efforts, at the
national and global levels, toward the control of carbapenem-
resistance among A. baumannii isolates worldwide.
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Supplemental Figure 1 | Presentation of study strategy to select
blaOXA-23
+A. baumannii clinical isolates for AFLP genotype
determination and DNA sequence analysis. Step-wise selection of blaOXA+
isolates was carried out using 2 sets of multiplex PCR assay, followed by AFLP
genotypic analysis and DNA sequencing of blaOXA-23-like gene amplicons.
Supplemental Figure 2 | Agarose gel electrophoresis analysis of PCR
amplicons specific for Ambler Class A and B carbapenemases. Genomic
DNA from clinical A. baumannii isolates were analyzed by uniplex and multiplex
PCR assay as described (M&M). Lanes 1 through 6; specific bands for (1) NDM1,
(2) IMP1, (3) VIM2, (4) SPM1, (5) blaGES, and (6) KPC encoding genes. Lane 7;
AB-hexaplex (AB-h) PCR products of the above genes. Lane 8; 100bp DNA
markers.
Supplemental Figure 3 | Comparison between DNA sequences of
AB0057Ref.seq and PCR amplicon sequences obtained from mutant
CR-AB isolates in genotype groups with >2 members showing a
10-nucleotide span in each direction of the point of mutation (total 21
nucleotides). (A) Alignment of amplicons from three isolates of AFLP group L
(i.e., TUMS/BTRF443, L2, and L3) as compared to the AB0057Ref.seq sequence,
with the mutation at position 766. (B) Alignment of AFLP groups E, C, and K
amplicons with the AB0057Ref.seq reference sequence, with the mutation at
position 771. In both panels (∗) indicates sequence identity (or homology), and (−)
shows the position of carbapenemase gene mutation.
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